Repligen Reports Fourth Quarter and Full Year 2023 Financial Results

Reports fourth quarter revenue of $156 million and full year revenue of $639 millionContinued strength in orders with fourth quarter book-to-bill ratio of 1.03

Related Keywords

Massachusetts ,United States ,Germany ,Waltham ,Ireland ,Sweden ,Canada ,Estonia ,Netherlands ,France ,China ,Sondras Newman , ,Exchange Commission The ,Securities Exchange ,Currency Exchange ,Revenue Growth ,Drug Administration ,European Medicines Evaluation Agency ,Linkedin ,Repligen Corporation ,Chief Executive Officer ,Fluid Management ,Tangential Flow Filtration ,Per Share ,Investor Relations ,Process Analytics ,Private Securities Litigation Reform Act ,Securities Act ,Securities Exchange Act ,Exchange Commission ,Annual Report ,Quarterly Reports ,Months Ended December ,Second Supplemental Indenture ,Sheet Data ,Reported Revenue Growth ,Organic Revenue Growth ,Total Revenue ,Base Revenue ,Adjusted Income ,Adjusted Net Income ,Earnings Per Share ,Adjusted Earnings Per Share ,Adjusted Cost ,Adjusted Rd Expense ,Income Guidiance ,Per Share Guidance ,Condensed Consolidated Statements ,Restructuring Plan ,Region ,